Company intelligence / Profile preview

Newesis

Newcastle upon Tyne, United Kingdomnewesis.com ↗

Ownership: Private
Development stage: Other

Overview

Newcells Biotech provides validated human in vitro tissue models—especially kidney, retina, and lung—to improve the predictive power of preclinical drug discovery. Their platforms are widely used by pharma/biotech companies to assess safety, efficacy, ADME properties, and reduce animal testing. The company’s models have been proven predictive in hundreds of customer studies.

Therapeutic areas: PulmonologyOphthalmologyNephrologyOther
Modalities: Induced pluripotent stem cell derived therapyOrganoid technology (as a platform for in vitro models)Cell-based assay systemsPrimary tissue models
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Newesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newesis.

Explore the full profile